Identifying Low-Abundance Biomarkers: Aptamer-Based Proteomics Potentially Enables More Sensitive Detection in Cardiovascular Diseases
Biomarkers are clinical, molecular, or image-based measurable parameters that can characterize an individual's specific biological state, whether normal, pathological or in response to treatment. A biomarker is considered of clinically valuable if: (i) it can be measured repeatedly with accuracy and relatively rapid clinical turnaround, (ii) it provides unique, superior information on patient status, and (iii) it aids in clinical decision-making with high precision1. High-quality biomarkers can critically inform clinical diagnosis (e.g. high-sensitivity troponin for acute myocardial infarction), and guide therapy (e.g. CYP2C19 status for clopidogrel therapy). The ideal biomarkers can further reveal underlying biological processes, inform therapeutic deployment, and pave the way for true personalized precision medicine. In this issue of Circulation, Ngo et al. demonstrates the use of a developing proteomics technology to rapidly screen for protein biomarkers in patients with planned and spontaneous myocardial infarcts.2
- Received May 11, 2016.
- Revision received May 29, 2016.
- Accepted June 27, 2016.